The global Dry Eye Disease market size is predicted to grow from US$ 6020 million in 2025 to US$ 7916 million in 2031; it is expected to grow at a CAGR of 4.7% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Dry Eye Disease (DED) drugs are pharmaceutical treatments designed to alleviate the symptoms and underlying causes of dry eye disease, a chronic condition characterized by insufficient tear production or poor tear quality. These drugs aim to restore tear film stability, reduce inflammation, and improve ocular surface health. Common types of DED drugs include artificial tears, anti-inflammatory agents like cyclosporine and lifitegrast, and medications that stimulate tear production. These treatments help relieve discomfort, prevent further eye damage, and enhance patients quality of life.

The Dry Eye Disease (DED) market is driven by the increasing prevalence of dry eye disease worldwide, largely due to aging populations, widespread digital device use, and environmental factors such as pollution and dry climates. Rising awareness about ocular health and improved diagnostic capabilities have led to higher rates of diagnosis and treatment initiation. Moreover, advancements in pharmaceutical research have introduced innovative drugs like lifitegrast and novel formulations of cyclosporine, offering better efficacy and patient compliance compared to traditional artificial tears. Growing demand from both developed and emerging markets, coupled with supportive government initiatives and reimbursement policies, continues to fuel the expansion of the DED drug market.

Despite promising growth, the Dry Eye Disease Drug market faces several challenges. The complex and multifactorial nature of dry eye disease makes it difficult to develop universally effective treatments, as patients often require personalized therapy regimens. Many existing drugs provide symptomatic relief rather than a permanent cure, which can lead to patient dissatisfaction and poor adherence. Additionally, high treatment costs and limited access to advanced therapies in low-income regions restrict market penetration. Regulatory hurdles and long approval timelines for novel drugs further slow market entry. To overcome these challenges, ongoing research into better-targeted therapies and cost-effective treatment options is essential.

Infinity Market Research newest research report, the Dry Eye Disease Industry Forecast looks at past sales and reviews total world Dry Eye Disease sales in 2024, providing a comprehensive analysis by region and market sector of projected Dry Eye Disease sales for 2025 through 2031. With Dry Eye Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dry Eye Disease industry.

This Insight Report provides a comprehensive analysis of the global Dry Eye Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dry Eye Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Dry Eye Disease market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dry Eye Disease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dry Eye Disease.

This report presents a comprehensive overview, market shares, and growth opportunities of Dry Eye Disease market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Artificial Tears
    Anti-inflammatory Drugs
    Other

Segmentation by Application:

    Hospital
    Drug Stores
    Online Pharmacies

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    AbbVie
    Alcon
    Novartis
    Santen Pharma
    Johnson & Johnson
    Bausch & Lomb
    Thea pharmaceuticals
    URSAPHARM
    SIMILASAN
    Akorn
    United Laboratories
    Sun Pharmaceutical
    Jianfeng Group
    OmniVision Pharma
    Rohto
    Prestige Consumer Healthcare
    LION
    Kenvue (VISINE)

Key Questions Addressed in this Report

What is the 10-year outlook for the global Dry Eye Disease market?
What factors are driving Dry Eye Disease market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Dry Eye Disease market opportunities vary by end market size?
How does Dry Eye Disease break out by Type, by Application?